89bio Inc. Reports Q1 2025 Financial Results

89Bio Inc ( (ETNB) ) has released its Q1 earnings. Here is a breakdown of the information 89Bio Inc presented to its investors.

89bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapies for liver and cardiometabolic diseases, with its lead candidate pegozafermin currently in Phase 3 trials. In its first quarter of 2025 earnings report, 89bio highlighted the progress of its Phase 3 trials for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG), alongside a strong cash position bolstered by a recent equity offering. The company reported a net loss of $71.3 million, driven by increased research and development expenses as it advances its clinical programs. Despite the losses, 89bio remains optimistic about its future, with upcoming data readouts expected to support accelerated approval for pegozafermin in treating MASH and SHTG. Looking forward, 89bio’s management is focused on maintaining momentum in its clinical trials and leveraging its global manufacturing strategy to support future commercialization efforts.